Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

1.

Tumor-associated mutations in a conserved structural motif alter physical and biochemical properties of human RAD51 recombinase.

Chen J, Morrical MD, Donigan KA, Weidhaas JB, Sweasy JB, Averill AM, Tomczak JA, Morrical SW.

Nucleic Acids Res. 2015 Jan;43(2):1098-111. doi: 10.1093/nar/gku1337. Epub 2014 Dec 24.

2.

A PHASE II TRIAL OF BALLOON-CATHETER PARTIAL BREAST BRACHYTHERAPY OPTIMIZATION IN THE TREATMENT OF STAGE 0, I AND IIA BREAST CARCINOMA.

Nath SK, Chen ZJ, Rowe BP, Blitzblau RC, Aneja S, Grube BJ, Horowitz NR, Weidhaas JB.

J Radiat Oncol. 2014 Dec;3(4):371-378.

PMID:
25485042
3.

A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.

Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S.

Clin Cancer Res. 2014 Sep 1;20(17):4499-510. doi: 10.1158/1078-0432.CCR-14-0348.

PMID:
25183481
4.

A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB.

Ann Oncol. 2014 Nov;25(11):2230-6. doi: 10.1093/annonc/mdu367. Epub 2014 Jul 31.

PMID:
25081901
5.

A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer.

Dorairaj JJ, Salzman DW, Wall D, Rounds T, Preskill C, Sullivan CA, Lindner R, Curran C, Lezon-Geyda K, McVeigh T, Harris L, Newell J, Kerin MJ, Wood M, Miller N, Weidhaas JB.

BMC Cancer. 2014 Jun 10;14:421. doi: 10.1186/1471-2407-14-421.

6.

Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer.

Chen X, Paranjape T, Stahlhut C, McVeigh T, Keane F, Nallur S, Miller N, Kerin M, Deng Y, Yao X, Zhao H, Weidhaas JB, Slack FJ.

Oncogene. 2015 Apr 16;34(16):2125-37. doi: 10.1038/onc.2014.117. Epub 2014 Jun 9.

PMID:
24909162
7.

Radiation therapy oncology group gynecologic oncology working group: comprehensive results.

Gaffney DK, Jhingran A, Portelance L, Viswanathan A, Schefter T, Weidhaas J, Small W Jr.

Int J Gynecol Cancer. 2014 Jun;24(5):956-62. doi: 10.1097/IGC.0000000000000135.

PMID:
24819663
8.

The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905.

Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J.

PLoS One. 2014 Apr 14;9(4):e94167. doi: 10.1371/journal.pone.0094167. eCollection 2014.

9.

Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.

Kim M, Chen X, Chin LJ, Paranjape T, Speed WC, Kidd KK, Zhao H, Weidhaas JB, Slack FJ.

Cell Cycle. 2014;13(6):1030-40. doi: 10.4161/cc.27941. Epub 2014 Feb 3.

10.

Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary.

Wallner PE, Anscher MS, Barker CA, Bassetti M, Bristow RG, Cha YI, Dicker AP, Formenti SC, Graves EE, Hahn SM, Hei TK, Kimmelman AC, Kirsch DG, Kozak KR, Lawrence TS, Marples B, McBride WH, Mikkelsen RB, Park CC, Weidhaas JB, Zietman AL, Steinberg M.

Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):11-7. doi: 10.1016/j.ijrobp.2013.09.040. Epub 2013 Nov 15. Erratum in: Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1115.

PMID:
24246724
11.

SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers.

Preskill C, Weidhaas JB.

Crit Rev Oncog. 2013;18(4):327-40. Review.

12.

SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer.

Salzman DW, Weidhaas JB.

Pharmacol Ther. 2013 Jan;137(1):55-63. doi: 10.1016/j.pharmthera.2012.08.016. Epub 2012 Sep 3. Review.

13.

Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma.

Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, Slack FJ.

Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):E1695-704. doi: 10.1073/pnas.1201516109. Epub 2012 Jun 8.

14.

A prospective, multicenter study of complementary/alternative medicine (CAM) utilization during definitive radiation for breast cancer.

Moran MS, Ma S, Jagsi R, Yang TJ, Higgins SA, Weidhaas JB, Wilson LD, Lloyd S, Peschel R, Gaudreau B, Rockwell S.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):40-6. doi: 10.1016/j.ijrobp.2012.03.025. Epub 2012 Jun 1.

PMID:
22658441
15.

A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis.

Grechukhina O, Petracco R, Popkhadze S, Massasa E, Paranjape T, Chan E, Flores I, Weidhaas JB, Taylor HS.

EMBO Mol Med. 2012 Mar;4(3):206-17. doi: 10.1002/emmm.201100200. Epub 2012 Feb 3.

16.

KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.

Kundu ST, Nallur S, Paranjape T, Boeke M, Weidhaas JB, Slack FJ.

Cell Cycle. 2012 Jan 15;11(2):361-6. doi: 10.4161/cc.11.2.18794. Epub 2012 Jan 15.

PMID:
22189714
17.

A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.

Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB.

Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5.

18.

Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells.

Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM, Slack FJ.

Cancer Biol Ther. 2011 Nov 15;12(10):908-14. doi: 10.4161/cbt.12.10.17681. Epub 2011 Nov 15.

19.

miRNAs in the spotlight: Making 'silent' mutations speak up.

Salzman DW, Weidhaas JB.

Nat Med. 2011 Aug 4;17(8):934-5. doi: 10.1038/nm0811-934. No abstract available.

PMID:
21818091
20.

MicroRNA signatures differentiate melanoma subtypes.

Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban R, Krauthammer M, Tuck D, Slack FJ, Weidhaas JB.

Cell Cycle. 2011 Jun 1;10(11):1845-52. Epub 2011 Jun 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk